ACET
Price
$0.81
Change
+$0.05 (+6.58%)
Updated
Sep 18 closing price
Capitalization
68.16M
47 days until earnings call
VIVS
Price
$3.88
Change
+$0.24 (+6.59%)
Updated
Sep 18, 04:56 PM (EDT)
Capitalization
10.1M
Interact to see
Advertisement

ACET vs VIVS

Header iconACET vs VIVS Comparison
Open Charts ACET vs VIVSBanner chart's image
Adicet Bio
Price$0.81
Change+$0.05 (+6.58%)
Volume$372.92K
Capitalization68.16M
VivoSim Lab
Price$3.88
Change+$0.24 (+6.59%)
Volume$100
Capitalization10.1M
ACET vs VIVS Comparison Chart in %
Loading...
ACET
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VIVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ACET vs. VIVS commentary
Sep 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACET is a Hold and VIVS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 19, 2025
Stock price -- (ACET: $0.82 vs. VIVS: $3.88)
Brand notoriety: ACET and VIVS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ACET: 73% vs. VIVS: 13%
Market capitalization -- ACET: $68.16M vs. VIVS: $10.1M
ACET [@Biotechnology] is valued at $68.16M. VIVS’s [@Biotechnology] market capitalization is $10.1M. The market cap for tickers in the [@Biotechnology] industry ranges from $99.25B to $0. The average market capitalization across the [@Biotechnology] industry is $1.92B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACET’s FA Score shows that 2 FA rating(s) are green whileVIVS’s FA Score has 1 green FA rating(s).

  • ACET’s FA Score: 2 green, 3 red.
  • VIVS’s FA Score: 1 green, 4 red.
According to our system of comparison, ACET is a better buy in the long-term than VIVS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACET’s TA Score shows that 6 TA indicator(s) are bullish while VIVS’s TA Score has 5 bullish TA indicator(s).

  • ACET’s TA Score: 6 bullish, 4 bearish.
  • VIVS’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, ACET is a better buy in the short-term than VIVS.

Price Growth

ACET (@Biotechnology) experienced а -7.18% price change this week, while VIVS (@Biotechnology) price change was +5.14% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.03%. For the same industry, the average monthly price growth was +12.13%, and the average quarterly price growth was +38.54%.

Reported Earning Dates

ACET is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+2.03% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ACET($68.2M) has a higher market cap than VIVS($10.1M). VIVS YTD gains are higher at: 744.749 vs. ACET (-14.896). VIVS has higher annual earnings (EBITDA): -1.72M vs. ACET (-112.08M). ACET has more cash in the bank: 125M vs. VIVS (9.06M). VIVS has less debt than ACET: VIVS (822K) vs ACET (15.4M). VIVS has higher revenues than ACET: VIVS (142K) vs ACET (0).
ACETVIVSACET / VIVS
Capitalization68.2M10.1M675%
EBITDA-112.08M-1.72M6,532%
Gain YTD-14.896744.749-2%
P/E RatioN/AN/A-
Revenue0142K-
Total Cash125M9.06M1,380%
Total Debt15.4M822K1,873%
FUNDAMENTALS RATINGS
ACET vs VIVS: Fundamental Ratings
ACET
VIVS
OUTLOOK RATING
1..100
1130
VALUATION
overvalued / fair valued / undervalued
1..100
27
Undervalued
25
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9896
PRICE GROWTH RATING
1..100
5934
P/E GROWTH RATING
1..100
18100
SEASONALITY SCORE
1..100
6550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

VIVS's Valuation (25) in the Biotechnology industry is in the same range as ACET (27) in the Medical Distributors industry. This means that VIVS’s stock grew similarly to ACET’s over the last 12 months.

VIVS's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ACET (100) in the Medical Distributors industry. This means that VIVS’s stock grew similarly to ACET’s over the last 12 months.

VIVS's SMR Rating (96) in the Biotechnology industry is in the same range as ACET (98) in the Medical Distributors industry. This means that VIVS’s stock grew similarly to ACET’s over the last 12 months.

VIVS's Price Growth Rating (34) in the Biotechnology industry is in the same range as ACET (59) in the Medical Distributors industry. This means that VIVS’s stock grew similarly to ACET’s over the last 12 months.

ACET's P/E Growth Rating (18) in the Medical Distributors industry is significantly better than the same rating for VIVS (100) in the Biotechnology industry. This means that ACET’s stock grew significantly faster than VIVS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ACETVIVS
RSI
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 2 days ago
86%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 2 days ago
81%
MACD
ODDS (%)
Bullish Trend 1 day ago
89%
Bullish Trend 2 days ago
83%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
88%
Bullish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 2 days ago
80%
Advances
ODDS (%)
Bullish Trend 10 days ago
82%
Bullish Trend 4 days ago
80%
Declines
ODDS (%)
Bearish Trend 4 days ago
88%
Bearish Trend 2 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 2 days ago
65%
View a ticker or compare two or three
Interact to see
Advertisement
ACET
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VIVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CMPX3.680.17
+4.99%
Compass Therapeutics
BNT70.641.37
+1.98%
Brookfield Wealth Solutions Ltd
RNG31.860.32
+1.01%
RINGCENTRAL
MMLP3.090.02
+0.65%
Martin Midstream Partners LP
RNAZ11.23-0.13
-1.14%
TransCode Therapeutics Inc

ACET and

Correlation & Price change

A.I.dvisor indicates that over the last year, ACET has been loosely correlated with SYRE. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if ACET jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACET
1D Price
Change %
ACET100%
+7.70%
SYRE - ACET
45%
Loosely correlated
+1.66%
IPSC - ACET
44%
Loosely correlated
+1.42%
OGI - ACET
41%
Loosely correlated
+5.93%
RGNX - ACET
41%
Loosely correlated
+3.77%
DVAX - ACET
39%
Loosely correlated
+1.78%
More

VIVS and

Correlation & Price change

A.I.dvisor indicates that over the last year, VIVS has been loosely correlated with LVTX. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if VIVS jumps, then LVTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VIVS
1D Price
Change %
VIVS100%
+6.73%
LVTX - VIVS
42%
Loosely correlated
-1.67%
GLTO - VIVS
38%
Loosely correlated
+0.70%
ORMP - VIVS
37%
Loosely correlated
+7.93%
ACET - VIVS
27%
Poorly correlated
+7.70%
KRRO - VIVS
26%
Poorly correlated
+9.58%
More